Last reviewed · How we verify
rhG-CSF+rhGM-CSF group
This combination of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) stimulates the production and activation of neutrophils and myeloid cells to enhance immune function and hematopoietic recovery.
This combination of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) stimulates the production and activation of neutrophils and myeloid cells to enhance immune function and hematopoietic recovery. Used for Chemotherapy-induced neutropenia, Hematopoietic stem cell transplantation support, Bone marrow recovery enhancement.
At a glance
| Generic name | rhG-CSF+rhGM-CSF group |
|---|---|
| Also known as | Topleucon®, Granulocyte Macrophage Colony Stimulating Factor, Granulocyte Colony Stimulating Factor |
| Sponsor | Xiamen Amoytop Biotech Co., Ltd. |
| Drug class | Hematopoietic growth factor combination |
| Target | G-CSF receptor; GM-CSF receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology; Hematology |
| Phase | FDA-approved |
Mechanism of action
rhG-CSF and rhGM-CSF are cytokines that bind to their respective receptors on hematopoietic progenitor cells, promoting differentiation and proliferation of granulocytes and macrophages. The combination approach leverages complementary signaling pathways to achieve enhanced mobilization of bone marrow-derived cells and improved immune cell function, particularly useful in settings of chemotherapy-induced neutropenia or hematopoietic stem cell transplantation.
Approved indications
- Chemotherapy-induced neutropenia
- Hematopoietic stem cell transplantation support
- Bone marrow recovery enhancement
Common side effects
- Bone pain
- Fever
- Fatigue
- Injection site reactions
- Splenomegaly
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhG-CSF+rhGM-CSF group CI brief — competitive landscape report
- rhG-CSF+rhGM-CSF group updates RSS · CI watch RSS
- Xiamen Amoytop Biotech Co., Ltd. portfolio CI